kabutan

Perseus Proteomics Inc.(4882) Summary

4882
TSE Growth
Perseus Proteomics Inc.
217
JPY
-1
(-0.46%)
Apr 30, 11:18 am JST
1.35
USD
Apr 29, 10:18 pm EDT
Result
PTS
outside of trading hours
216.1
Apr 30, 11:09 am JST
Summary Chart Historical News Financial Result
PER
PBR
4.58
Yield
ー%
Margin Trading Ratio
816.02
Stock Price
Apr 30, 2026
Opening Apr 30, 9:00 am
216 JPY 1.34 USD
Previous Close Apr 28
218 JPY 1.36 USD
High Apr 30, 9:12 am
217 JPY 1.35 USD
Low Apr 30, 10:55 am
213 JPY 1.32 USD
Volume
53,900
Trading Value
0.01B JPY 0.07M USD
VWAP
214.93 JPY 1.34 USD
Minimum Trading Value
21,700 JPY 135 USD
Market Cap
3.69B JPY 0.02B USD
Number of Trades
58
Liquidity & Number of Trades
As of Apr 30, 2026
Liquidity
Slightly High
1-Year Average
527
1-Year High Mar 9, 2026
13,130
Margin Trading
Date Short Interest Long Margin Positions Ratio
Apr 24, 2026 0 2,442,400
Apr 17, 2026 0 2,485,400
Apr 10, 2026 0 2,475,700
Apr 3, 2026 0 2,382,900
Mar 27, 2026 0 2,392,400
Company Profile
Perseus Proteomics Inc. is a biotech venture company specializing in the development of high-performance antibody drugs and research reagents targeting cancer.
Sector
Pharmaceuticals
Perseus Proteomics Inc. is a biotech venture company that leverages its academic drug discovery network originating from the University of Tokyo to conduct research and development of antibody drugs. Utilizing proprietary antibody acquisition and engineering technologies, the company is advancing the development of therapeutic antibodies targeting cancer and hematological diseases. Its main pipeline includes PPMX-T002, a radioisotope-labeled antibody targeting cadherin 3, and PPMX-T003, an antibody targeting transferrin receptor 1. The company's revenue is derived from upfront payments from out-licensing drug candidates to domestic and international pharmaceutical companies, milestone payments based on development progress, and royalty income as a percentage of sales after market launch.